These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 31054856)
1. GLS1 promotes proliferation in hepatocellular carcinoma cells via AKT/GSK3β/CyclinD1 pathway. Xi J; Sun Y; Zhang M; Fa Z; Wan Y; Min Z; Xu H; Xu C; Tang J Exp Cell Res; 2019 Aug; 381(1):1-9. PubMed ID: 31054856 [TBL] [Abstract][Full Text] [Related]
2. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway. Li B; Cao Y; Meng G; Qian L; Xu T; Yan C; Luo O; Wang S; Wei J; Ding Y; Yu D EBioMedicine; 2019 Jan; 39():239-254. PubMed ID: 30555042 [TBL] [Abstract][Full Text] [Related]
3. PES1 enhances proliferation and tumorigenesis in hepatocellular carcinoma via the PI3K/AKT pathway. Wang J; Sun J; Zhang N; Yang R; Li H; Zhang Y; Chen K; Kong D Life Sci; 2019 Feb; 219():182-189. PubMed ID: 30630006 [TBL] [Abstract][Full Text] [Related]
4. HJURP promotes hepatocellular carcinoma proliferation by destabilizing p21 via the MAPK/ERK1/2 and AKT/GSK3β signaling pathways. Chen T; Huang H; Zhou Y; Geng L; Shen T; Yin S; Zhou L; Zheng S J Exp Clin Cancer Res; 2018 Aug; 37(1):193. PubMed ID: 30111352 [TBL] [Abstract][Full Text] [Related]
5. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target. Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213 [No Abstract] [Full Text] [Related]
6. MicroRNA-23b functions as an oncogene and activates AKT/GSK3β/β-catenin signaling by targeting ST7L in hepatocellular carcinoma. Zhuang L; Wang X; Wang Z; Ma X; Han B; Zou H; Wu Z; Dong S; Qu Z; Zang Y; Wu L Cell Death Dis; 2017 May; 8(5):e2804. PubMed ID: 28518144 [TBL] [Abstract][Full Text] [Related]
7. PDCD6 Promotes Hepatocellular Carcinoma Cell Proliferation and Metastasis through the AKT/GSK3β/β-catenin Pathway. Wen SY; Liu YT; Wei BY; Ma JQ; Chen YY Biomed Environ Sci; 2023 Mar; 36(3):241-252. PubMed ID: 37005078 [TBL] [Abstract][Full Text] [Related]
8. Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma. Yu D; Shi X; Meng G; Chen J; Yan C; Jiang Y; Wei J; Ding Y Oncotarget; 2015 Apr; 6(10):7619-31. PubMed ID: 25844758 [TBL] [Abstract][Full Text] [Related]
9. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway. Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993 [TBL] [Abstract][Full Text] [Related]
10. Glutaminase 2 negatively regulates the PI3K/AKT signaling and shows tumor suppression activity in human hepatocellular carcinoma. Liu J; Zhang C; Lin M; Zhu W; Liang Y; Hong X; Zhao Y; Young KH; Hu W; Feng Z Oncotarget; 2014 May; 5(9):2635-47. PubMed ID: 24797434 [TBL] [Abstract][Full Text] [Related]
11. As an independent prognostic factor, FAT10 promotes hepatitis B virus-related hepatocellular carcinoma progression via Akt/GSK3β pathway. Liu L; Dong Z; Liang J; Cao C; Sun J; Ding Y; Wu D Oncogene; 2014 Feb; 33(7):909-20. PubMed ID: 23812429 [TBL] [Abstract][Full Text] [Related]
12. PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3β/Snail signaling. Jiang H; Zhou Z; Jin S; Xu K; Zhang H; Xu J; Sun Q; Wang J; Xu J Cancer Sci; 2018 May; 109(5):1414-1427. PubMed ID: 29603830 [TBL] [Abstract][Full Text] [Related]
13. GOT2 Silencing Promotes Reprogramming of Glutamine Metabolism and Sensitizes Hepatocellular Carcinoma to Glutaminase Inhibitors. Li Y; Li B; Xu Y; Qian L; Xu T; Meng G; Li H; Wang Y; Zhang L; Jiang X; Liu Q; Xie Y; Cheng C; Sun B; Yu D Cancer Res; 2022 Sep; 82(18):3223-3235. PubMed ID: 35895805 [TBL] [Abstract][Full Text] [Related]
14. Wogonin inhibits cell cycle progression by activating the glycogen synthase kinase-3 beta in hepatocellular carcinoma. Hong M; Almutairi MM; Li S; Li J Phytomedicine; 2020 Mar; 68():153174. PubMed ID: 31991293 [TBL] [Abstract][Full Text] [Related]
15. Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway. Yang X; Feng Y; Liu Y; Ye X; Ji X; Sun L; Gao F; Zhang Q; Li Y; Zhu B; Wang X Phytomedicine; 2021 Jul; 87():153575. PubMed ID: 33984593 [TBL] [Abstract][Full Text] [Related]
16. Epithelial V-like antigen 1 promotes hepatocellular carcinoma growth and metastasis via the ERBB-PI3K-AKT pathway. Ni Q; Chen Z; Zheng Q; Xie D; Li JJ; Cheng S; Ma X Cancer Sci; 2020 May; 111(5):1500-1513. PubMed ID: 31997489 [TBL] [Abstract][Full Text] [Related]
17. STK17B promotes carcinogenesis and metastasis via AKT/GSK-3β/Snail signaling in hepatocellular carcinoma. Lan Y; Han J; Wang Y; Wang J; Yang G; Li K; Song R; Zheng T; Liang Y; Pan S; Liu X; Zhu M; Liu Y; Meng F; Mohsin M; Cui Y; Zhang B; Subash S; Liu L Cell Death Dis; 2018 Feb; 9(2):236. PubMed ID: 29445189 [TBL] [Abstract][Full Text] [Related]
18. SHP2 promotes proliferation of breast cancer cells through regulating Cyclin D1 stability Yuan Y; Fan Y; Gao Z; Sun X; Zhang H; Wang Z; Cui Y; Song W; Wang Z; Zhang F; Niu R Cancer Biol Med; 2020 Aug; 17(3):707-725. PubMed ID: 32944401 [No Abstract] [Full Text] [Related]
19. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway. Fu X; Wen H; Jing L; Yang Y; Wang W; Liang X; Nan K; Yao Y; Tian T Cancer Sci; 2017 Apr; 108(4):620-631. PubMed ID: 28132399 [TBL] [Abstract][Full Text] [Related]
20. ZNF452 facilitates tumor proliferation and invasion via activating AKT-GSK3β signaling pathway and predicts poor prognosis of non-small cell lung cancer patients. Zhang X; Zhou H; Zhang Y; Cai L; Jiang G; Li A; Miao Y; Li Q; Qiu X; Wang E Oncotarget; 2017 Jun; 8(24):38863-38875. PubMed ID: 28418919 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]